• Medicine
  • Published in Cancer research 1985

Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

@article{Stanton1985PhaseIA,
  title={Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.},
  author={G F Stanton and Vincent Raymond and Robert E. Wittes and Peter Schulman and D Budman and Robin Baratz and Lynne Williams and Gina R. Petroni and Nancy L. Geller and Cynthia Hancock},
  journal={Cancer research},
  year={1985},
  volume={45 4},
  pages={
          1862-8
        }
}
We have conducted a Phase I and initial clinical pharmacological evaluation of 4'-deoxydoxorubicin (4'-DXDX), administering the drug i.v. on an every 21-day schedule to 60 patients with advanced cancer. Patients were treated at six dosage levels ranging from 10 to 35 mg/sq m. Leukopenia was the dose-limiting toxic effect, and no cardiac, renal, or hepatic toxicity was observed; stomatitis was not seen; and there were no drug-related deaths. Significant alopecia was rare at doses less than 35 mg… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Occurrence of circulating 7-deoxyaglycone metabolites of 4′-deoxydoxorubicin in man

  • Cancer Chemotherapy and Pharmacology
  • 1987
VIEW 2 EXCERPTS
CITES BACKGROUND & RESULTS